Clinical Trials Browser

Skin Neoplasms × cemiplimab × Dermatologic × Clear all

NCT07387198 2026-04-17

NeoMatryx

Phase 2 Not yet recruiting

Skin Neoplasms, Carcinoma, Merkel Cell

NCT06585410 2026-04-08

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

Phase 3 Recruiting

Skin Neoplasms

NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Phase 1 Active not recruiting

Skin Neoplasms

NCT06981325 2026-03-11

CEMI-first

Phase 2 Recruiting

Carcinoma, Basal Cell, Skin Neoplasms

NCT06171750 2026-03-06

ANCHOR

Phase 1 Recruiting

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Skin Neoplasms

NCT06190951 2026-02-10

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

Phase 2 Active not recruiting

Melanoma, Skin Neoplasms

NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Phase EARLY_PHASE1 Active not recruiting

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

NCT06022029 2025-12-24

ON-5001

Phase 1 Recruiting

BreastDermatologicGenitourinaryGynecologicHead & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Bites and Stings, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma in Situ, Uterine Cervical Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Skin Neoplasms, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Triple Negative Breast Neoplasms

NCT04315701 2025-11-20

A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer

Phase 2 Active not recruiting

Skin Neoplasms

NCT05574101 2025-08-08

A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer

Phase 2 Active not recruiting

Carcinoma, Squamous Cell, Skin Neoplasms

NCT05608291 2025-05-13

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Phase 3 Active not recruiting

Melanoma, Skin Neoplasms

NCT03684785 2022-04-07

Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors

Phase 1/2 Terminated

Melanoma, Skin Neoplasms, Carcinoma, Merkel Cell